Novel design principle validated: glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent.
2-Naphthyl-substituted glucopyranosylidene-spiro-oxathiazole prepared following a novel design principle was found to be the best known glucose analogue inhibitor of rabbit muscle glycogen phosphorylase b (K(i) 160 nM).
Somsák
László
L
Department of Organic Chemistry, University of Debrecen, PO Box 20, H-4010 Debrecen, Hungary. somsak@tigris.unideb.hu
Nagy
Veronika
V
Vidal
Sébastien
S
Czifrák
Katalin
K
Berzsényi
Eszter
E
Praly
Jean-Pierre
JP
D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D015195:Drug Design; D005947:Glucose / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D006003:Glycogen / Q000737:chemistry; D024981:Glycogen Phosphorylase / Q000037:antagonists & inhibitors* / Q000737:chemistry; D007004:Hypoglycemic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D007700:Kinetics; D008956:Models, Chemical; D011817:Rabbits; D013141:Spiro Compounds / Q000138:chemical synthesis* / Q000494:pharmacology; D013844:Thiazoles / Q000138:chemical synthesis* / Q000494:pharmacology
D007004:Hypoglycemic Agents; D013141:Spiro Compounds; D013844:Thiazoles; C540068:glucopyranosylidene-spiro-oxathiazole; D006003:Glycogen; D024981:Glycogen Phosphorylase; D005947:Glucose